These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 28163106)

  • 1. Angiogenesis regulation by nanocarriers bearing RNA interference.
    Ofek P; Tiram G; Satchi-Fainaro R
    Adv Drug Deliv Rev; 2017 Sep; 119():3-19. PubMed ID: 28163106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendrimer-mediated targeting of angiogenic biomarkers: therapeutic intervention against cancer.
    Pathak A; Jain NK; Jain K
    Expert Opin Drug Deliv; 2024 Aug; 21(8):1235-1250. PubMed ID: 39161976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct cytosolic siRNA delivery by reconstituted high density lipoprotein for target-specific therapy of tumor angiogenesis.
    Ding Y; Wang Y; Zhou J; Gu X; Wang W; Liu C; Bao X; Wang C; Li Y; Zhang Q
    Biomaterials; 2014 Aug; 35(25):7214-27. PubMed ID: 24875759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-Based Nanoparticles Delivery Systems for Targeted Cancer Therapy: Lessons from Anti-Angiogenesis Treatments.
    de la Torre P; Pérez-Lorenzo MJ; Alcázar-Garrido Á; Flores AI
    Molecules; 2020 Feb; 25(3):. PubMed ID: 32046010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical and clinical development of siRNA-based therapeutics.
    Ozcan G; Ozpolat B; Coleman RL; Sood AK; Lopez-Berestein G
    Adv Drug Deliv Rev; 2015 Jun; 87():108-19. PubMed ID: 25666164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Tumor Endothelial Cells with Nanoparticles.
    Sakurai Y; Akita H; Harashima H
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31756900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanocarriers for treatment of ocular neovascularization in the back of the eye: new vehicles for ophthalmic drug delivery.
    Shen HH; Chan EC; Lee JH; Bee YS; Lin TW; Dusting GJ; Liu GS
    Nanomedicine (Lond); 2015; 10(13):2093-107. PubMed ID: 26096379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy.
    Ku SH; Kim K; Choi K; Kim SH; Kwon IC
    Adv Healthc Mater; 2014 Aug; 3(8):1182-93. PubMed ID: 24577795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Curcumin Capped Copper Nanoparticles as Possible Inhibitors of Human Breast Cancer Cells and Angiogenesis: a Comparative Study with Native Curcumin.
    Kamble S; Utage B; Mogle P; Kamble R; Hese S; Dawane B; Gacche R
    AAPS PharmSciTech; 2016 Oct; 17(5):1030-41. PubMed ID: 26729534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoparticle Delivery Systems for DNA/RNA and their Potential Applications in Nanomedicine.
    Shen H; Huang X; Min J; Le S; Wang Q; Wang X; Dogan AA; Liu X; Zhang P; Draz MS; Xiao J
    Curr Top Med Chem; 2019; 19(27):2507-2523. PubMed ID: 31775591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Advances in Nanomedicine for Ocular Fundus Neovascularization Disease Management.
    Zhou Y; Xu M; Shen W; Xu Y; Shao A; Xu P; Yao K; Han H; Ye J
    Adv Healthc Mater; 2024 Jul; 13(17):e2304626. PubMed ID: 38406994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene delivery nanoparticles to modulate angiogenesis.
    Kim J; Mirando AC; Popel AS; Green JJ
    Adv Drug Deliv Rev; 2017 Sep; 119():20-43. PubMed ID: 27913120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities.
    Zhang J; Li J; Shi Z; Yang Y; Xie X; Lee SM; Wang Y; Leong KW; Chen M
    Acta Biomater; 2017 Aug; 58():349-364. PubMed ID: 28455219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advances and Strategies in Tumor Vasculature Targeted Nano-Drug Delivery Systems.
    Ying M; Chen G; Lu W
    Curr Pharm Des; 2015; 21(22):3066-75. PubMed ID: 26027578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-angiogenic therapies in cancer: achievements and open questions.
    Ruegg C; Mutter N
    Bull Cancer; 2007 Sep; 94(9):753-62. PubMed ID: 17878094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review: Integrin alphavbeta3-targeted molecular imaging and therapy in angiogenesis.
    Lim EH; Danthi N; Bednarski M; Li KC
    Nanomedicine; 2005 Jun; 1(2):110-4. PubMed ID: 17292065
    [No Abstract]   [Full Text] [Related]  

  • 18. Liposomal delivery of vascular endothelial growth factor/receptors and their inhibitors.
    Khodabakhsh F; Muyldermans S; Behdani M; Kazemi-Lomedasht F
    J Drug Target; 2020 Apr; 28(4):379-385. PubMed ID: 31822133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organic Nanocarriers for Bevacizumab Delivery: An Overview of Development, Characterization and Applications.
    Alves ACS; Bruinsmann FA; Guterres SS; Pohlmann AR
    Molecules; 2021 Jul; 26(14):. PubMed ID: 34299401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulating angiogenesis with integrin-targeted nanomedicines.
    Duro-Castano A; Gallon E; Decker C; Vicent MJ
    Adv Drug Deliv Rev; 2017 Sep; 119():101-119. PubMed ID: 28502767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.